CNEUPRO - Clinical Neuroproteomics of Neurodegenerative Diseases (Life sciences, genomics and biotechnology for health) (»add to infobox)

Alzheimer's dementia (AD) is one of the most common brain diseases in the elderly. Dementias pose a major health problem in European countries, with currently 5.7 million affected dementia patients in the EU25. Currently no curative therapies are available for these dementias, however, first disease-modifying treatment strategies like Abeta-immunisation have entered clinical trials. These novel treatments will be most effective if they are offered at a very early dementia stage. However, the reliable clinical differential diagnosis of very early dementia stages is not satisfactory. Here, recent research has clearly demonstrated that multiparametric neurochemical dementia diagnostics (NDD) in cerebrospinal fluid (CSF) does improve the early and differential diagnosis of dementias. cNEUPRO will apply advanced proteomic tools to discover novel neurochemical dementia markers (BIOMARKERS) in blood and CSF for the improved early and possibly predictive diagnosis of AD. A predictive dementia diagnosis will support the most effective use of forthcoming preventive therapeutic strategies. Our initiative will establish European SOPs for current neurochemical dementia diagnostics (NDD) and we will establish first NDD reference centres in Portugal and Hungary. A strong methodological impact is put on the quality of pre-analytical sample handling and clinical phenotypyng, which has been neglected in industry-driven discovery studies. cNEUPRO integrates innovative biotech and bioinformatic companies with leading clinical and proteomic dementia research centres. cNEUPRO will also support the discovery of new diagnostic targets and is also promising to identify novel scaffolds for advanced molecular neuroimaging. Accordingly, cNEUPRO will contribute considerably to the welfare, health and quality of life in Europe, and concomitantly it will reinforce the competitiveness of the European biotech industry.

COORDINATOR (1/1)

PARTICIPANTS (16/16)

RELATED THEMATIC AREAS (1/1)